S Djelbani-Ahmed1,2, M O Chandesris3,4,5, A Mekinian6, D Canioni3,5,7, C Brouzes3,5,8, K Hanssens3,9, G Pop1, I Durieu10, S Durupt10, B Grosbois11, S Besnard11, O Tournilhac12, O Beyne-Rauzy13, P Agapé14, A Delmer15, D Ranta16, P Y Jeandel17, S Georgin-Lavialle18, L Frenzel3,4,5, G Damaj3,19, V Eder1, O Lortholary3,5,20, O Hermine3,4,5, O Fain6, M Soussan21,22. 1. Department of Nuclear Medicine, Avicenne Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Bobigny, France. 2. Sorbonne Paris Cité, Paris 13 University, Bobigny, France. 3. French Reference center for Mastocytosis (Centre de Référence des Mastocytoses, CEREMAST), Necker Children's Hospital, APHP, Paris, France. 4. Department of Haematology, Necker Children's Hospital, APHP, Paris, France. 5. Sorbonne Paris Cité, Imagine Institute, Paris Descartes University, Paris, France. 6. Department of Internal Medicine and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), AP-HP, Saint Antoine Hospital, Paris, France. 7. Department of Pathology, Necker Children's Hospital, APHP, Paris, France. 8. Laboratory of Haematology, Necker Children's Hospital, APHP, Paris, France. 9. INSERM U1068, Centre de Recherche en Cancérologie de Marseille (Signaling, Hematopoiesis and Mechanism of Oncogenesis), Paoli Calmettes Institute, Aix-Marseille University, Marseille, France. 10. Department of Internal and Vascular Medicine, Hospices Civils de Lyon, Groupe Hopitalier Sud, Université de Lyon, Pierre-Bénite, France. 11. Department of Internal Medicine, Rennes University Hospital, Rennes, France. 12. Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France. 13. Department of Internal Medicine, Purpan University Hospital, Toulouse, France. 14. Department of Oncology and Haematology, Saint-Denis University Hospital, Saint-Denis de la Réunion, France. 15. Department of Haematology, Reims University Hospital, Reims, France. 16. Department of Haematology, Brabois University Hospital, Vandoeuvre les Nancy, France. 17. Department of Internal Medicine, Nice University Hospital, Nice, France. 18. Department of Internal Medicine, Tenon Hospital, Paris, France. 19. Department of Haematology, Caen University Hospital, Caen, France. 20. Department of Infectious Diseases and Tropical Medicine, Necker Children's Hospital, APHP, Pasteur Institute, Paris, France. 21. Department of Nuclear Medicine, Avicenne Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Bobigny, France. michael.soussan@avc.aphp.fr. 22. Sorbonne Paris Cité, Paris 13 University, Bobigny, France. michael.soussan@avc.aphp.fr.
Abstract
INTRODUCTION: Mastocytosis is a clonal haematological disease characterized by uncontrolled proliferation and the activation of mast cells. The value of FDG-PET/CT (FDG-PET) in mastocytosis has yet to be determined. METHODS: We retrospectively identified patients with an established diagnosis of systemic mastocytosis (SM), according to the WHO criteria, who underwent PET using the French Reference Centre for Mastocytosis database. Semi-quantitative and visual analysis of FDG-PET was performed and compared to the clinico-biological data. RESULTS: Our cohort included 19 adult patients, median age 65 years [range 58-74], including three with smouldering SM (SSM), three with aggressive SM (ASM), 10 with an associated clonal haematological non-mast-cell lineage disease (SM-AHNMD), and three with mast cell sarcoma (MCS). FDG-PET was performed at the time of the SM diagnosis (15/19), to evaluate lymph node (LN) activity (3/19) or the efficacy of therapy (1/19). FDG uptake was observed in the bone marrow (BM) (9/19, 47%), LN (6/19, 32%), spleen (12/19, 63%), or liver (1/19, 5%). No significant FDG uptake was observed in the SSM and ASM patients. A pathological FDG uptake was observed in the BM of 6/10 patients with SM-AHNMD, appearing as diffuse and homogeneous, and in the LN of 5/10 patients. All 3 MCS patients showed intense and multifocal BM pathological uptake, mimicking metastasis. No correlation was found between the FDG-PET findings and serum tryptase levels, BM mast cell infiltration percentage, and CD30 and CD2 expression by mast cells. CONCLUSIONS: FDG uptake does not appear to be a sensitive marker of mast cell activation or proliferation because no significant FDG uptake was observed in most common forms of mastocytosis (notably purely aggressive SM). However, pathological FDG uptake was observed in the SM-AHNMD and in MCS cases, suggesting a role of FDG-PET in their early identification and as a tool of therapeutic assessment in this subgroup of patients.
INTRODUCTION:Mastocytosis is a clonal haematological disease characterized by uncontrolled proliferation and the activation of mast cells. The value of FDG-PET/CT (FDG-PET) in mastocytosis has yet to be determined. METHODS: We retrospectively identified patients with an established diagnosis of systemic mastocytosis (SM), according to the WHO criteria, who underwent PET using the French Reference Centre for Mastocytosis database. Semi-quantitative and visual analysis of FDG-PET was performed and compared to the clinico-biological data. RESULTS: Our cohort included 19 adult patients, median age 65 years [range 58-74], including three with smouldering SM (SSM), three with aggressive SM (ASM), 10 with an associated clonal haematological non-mast-cell lineage disease (SM-AHNMD), and three with mast cell sarcoma (MCS). FDG-PET was performed at the time of the SM diagnosis (15/19), to evaluate lymph node (LN) activity (3/19) or the efficacy of therapy (1/19). FDG uptake was observed in the bone marrow (BM) (9/19, 47%), LN (6/19, 32%), spleen (12/19, 63%), or liver (1/19, 5%). No significant FDG uptake was observed in the SSM and ASM patients. A pathological FDG uptake was observed in the BM of 6/10 patients with SM-AHNMD, appearing as diffuse and homogeneous, and in the LN of 5/10 patients. All 3 MCS patients showed intense and multifocal BM pathological uptake, mimicking metastasis. No correlation was found between the FDG-PET findings and serum tryptase levels, BM mast cell infiltration percentage, and CD30 and CD2 expression by mast cells. CONCLUSIONS:FDG uptake does not appear to be a sensitive marker of mast cell activation or proliferation because no significant FDG uptake was observed in most common forms of mastocytosis (notably purely aggressive SM). However, pathological FDG uptake was observed in the SM-AHNMD and in MCS cases, suggesting a role of FDG-PET in their early identification and as a tool of therapeutic assessment in this subgroup of patients.
Authors: Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe Journal: Int Arch Allergy Immunol Date: 2011-10-27 Impact factor: 2.749
Authors: Emmanuel Itti; Michel Meignan; Alina Berriolo-Riedinger; Alberto Biggi; Amanda F Cashen; Pierre Véra; Hervé Tilly; Barry A Siegel; Andrea Gallamini; René-Olivier Casasnovas; Corinne Haioun Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-07 Impact factor: 9.236
Authors: Georg Zettinig; Alexander Becherer; Monika Szabo; Martin Uffmann; Robert Dudczak; Peter Valent; Kurt Kletter Journal: AJR Am J Roentgenol Date: 2002-11 Impact factor: 3.959
Authors: Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2010-07-13 Impact factor: 9.236